Gan & Lee Pharmaceuticals (SHA:603087) dosed the first subject for the phase I clinical trial of its GLR1023 injection, according to a Shanghai Stock Exchange filing on Thursday.
The drug, marketed as Cosentyx, is used to treat moderate to severe plaque psoriasis in adults. The trial aims to compare the similarity of the main pharmacokinetic parameters, immunogenicity and safety between a single subcutaneous injection of GLR1023 injection and secukinumab injection in healthy adult male subjects in China.
The Chinese pharmaceutical company invested 64.4 million yuan into the research and development of the drug, the filing said.
Shares of the company rose more than 2% in recent trade.
Price (RMB): ¥52.15, Change: ¥+1.3, Percent Change: +2.48%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。